Hybrid and Synthetic Vesicles Aim to Fix Extracellular Vesicle Therapy’s Biggest Flaws

Extracellular vesicles, the tiny lipid-bilayer particles that cells constantly release to shuttle proteins, lipids, and nucleic acids between one another, have become one of the most closely watched platforms in next-generation therapeutics. A mini-review published in AAPS Open by Zong-You Huang, Fang-Yi Hsu, Jia-Sin Chen, and Wei-Peng Li surveys how researchers are now engineering hybrid and synthetic versions of these vesicles to overcome the problems that have kept natural extracellular vesicles, or EVs, out of the clinic: low production yields, heterogeneous quality, high manufacturing costs, and limited control over functional engineering. The authors argue that scalable manufacturing combined with rational membrane engineering can turn these biological delivery vehicles into programmable nanosystems for drug delivery, cancer theranostics, immunotherapy, and beyond.

Natural EVs are attractive precisely because of what they are. Secreted by virtually every cell type, they carry cargo that mirrors their parent cells, including surface receptors, signaling proteins, enzymes, tetraspanins, bioactive lipids such as cholesterol and sphingolipids, and nucleic acids ranging from microRNA to messenger RNA and even DNA fragments. Found in blood, tissue fluid, and cerebrospinal fluid, they hold promise both as liquid biopsy biomarkers for diseases such as Alzheimer’s, cardiovascular disease, and cancer, and as targeted drug-delivery vehicles that exploit the body’s own intercellular communication system. But the review emphasizes that this biological richness comes at a price: the cargo of biogenic EVs reflects the physiological or pathological state of their source cells, and that heterogeneity creates serious obstacles for quality control, analysis, and clinical translation.

The first engineering strategy the authors describe replaces natural vesicles with artificial liposomes, which offer highly tunable and reproducible alternatives. Key parameters such as lipid composition, membrane fluidity, and surface functional groups can be precisely modulated to build programmable membrane architectures that are difficult to achieve in natural systems. Artificial liposomes can also serve as reconstitution platforms, integrating functional membrane proteins extracted from natural vesicles through extrusion or sonication-induced membrane refusion, producing functional vesicles at scale and at affordable cost. Membrane reconstitution itself remains technically demanding: the most widely adopted detergent-mediated approach inserts proteins in stochastic orientations, frequently yielding mixed inside-out and right-side-out configurations, and residual detergents can disrupt membrane packing and create vesicle-to-vesicle variability in protein loading. Newer methods that introduce proteins during liposome formation, including thin-film hydration, reverse-phase evaporation, and microfluidic assembly, can improve efficiency, but the authors note that none of these approaches reproduces the active regulatory machinery living cells use to control protein insertion and orientation.

Membrane fluidity emerges as a central design variable in this engineering effort. Lipid composition is the primary determinant of fluidity and phase behavior, and among commonly used lipids, DOPE, with its unsaturated acyl chains and small headgroup, promotes high lateral mobility and negative membrane curvature, lowering the energetic barriers to fusion, protein insertion, and lipid exchange. Cholesterol, by contrast, acts as a fluidity buffer, increasing membrane order and stability. Building on these principles, the review highlights liposome fusion-induced membrane exchange, or LIME, in which highly fluid DOPE-containing liposomes are brought into contact with living cells, fusing directly with native membranes and redistributing their lipids. This generates membrane-integrated liposomes while preserving key membrane-associated proteins, without harsh chemical treatments or genetic manipulation, and the authors describe it as a promising route toward low-heterogeneity vesicular systems for drug delivery and nanomedicine.

Complementary approaches extend beyond the lipid bilayer itself. Intracellular hydrogelation introduces hydrogel-forming precursors into living cells, where gelation is triggered by light activation or freezing; the resulting solid intracellular matrix physically confines biomacromolecules, allowing subsequent ultrasonication to enrich plasma membrane fragments free of cytoplasmic residuals. These membrane-enriched fragments can then serve as building blocks for reconstituted vesicles with preserved membrane functionality. On a parallel track, non-lipid synthetic vesicles built from polymers, peptides, or dendrimers replace lipid bilayers entirely, with assembly dictated by cross-linking chemistry and supramolecular design. Because these systems exhibit fixed topology and constrained lateral mobility, they can preserve spatial relationships among functional components for extended durations. The authors are careful to note that non-lipid vesicles are not intended to replace liposomes but to complement them, prioritizing structural persistence, reproducibility, and precision control. They also flag significant translational caveats: non-lipid materials may accumulate in the liver or spleen if not efficiently cleared, biodegradable versions may release metabolites with biological effects distinct from the intact vesicles, and novel polymers may face regulatory constraints.

Because artificially engineered vesicles cannot fully reproduce the complex biological interfaces of natural EVs, the review devotes substantial attention to surface membrane engineering. Direct chemical modification exploits reactive groups naturally present on membrane lipids, proteins, and glycoconjugates, such as amines, thiols, carboxyls, and hydroxyls, to install ligands covalently. Representative modifications include PEGylation to improve colloidal stability and circulation time, and conjugation of antibodies, peptides, aptamers, or small molecules to enhance cell-selective uptake. Hydrophobic anchors such as lipid tails and cholesterol derivatives can insert into the membrane to display functional molecules without disrupting the bilayer. The trade-off is real: limited site selectivity, variable coupling efficiency, and harsh reaction conditions can compromise membrane stability and reduce the biological functions inherited from the source membrane, so reaction chemistry, ligand density, and purification must be carefully optimized.

Two more selective strategies address these shortcomings. Bioorthogonal chemistry, descended from click chemistry and developed for living systems by Carolyn Bertozzi through copper-free strain-promoted azide-alkyne cycloaddition, offers superior chemoselectivity, allowing functional moieties to be installed with reduced off-target reactions. Typical reaction pairs, including azide/cyclooctyne and tetrazine/trans-cyclooctene, enable the same membrane scaffold to be rapidly adapted for different applications by swapping the conjugated component, whether a targeting ligand, imaging probe, or therapeutic cargo. Metabolic engineering takes an indirect route: cells are cultured with metabolite analogs bearing bioorthogonal motifs, such as azide-bearing sugars, which are incorporated into membrane glycans, lipids, and other biomolecules during normal biosynthesis. Vesicles derived from these engineered cells inherit the modified composition, enabling downstream click-based conjugation, and metabolic engineering can even alter the abundance of specific membrane components to improve targeting or immune evasion.

The review’s second major theme is membrane-camouflaged nanosystems, in which engineered single or hybrid membranes are wrapped around functional nanomaterial cores. Bare nanomaterials face substantial biological barriers in vivo, including nonspecific protein adsorption, rapid clearance by the mononuclear phagocyte system, and poor accumulation at pathological sites. Membrane coatings derived from whole cells, EVs, liposomes, or engineered vesicles can preserve membrane proteins, glycans, and lipids that regulate biodistribution and cell recognition, improving colloidal stability, prolonging circulation, and reducing immune recognition. Hybrid membrane strategies go further, integrating materials from two or more origins: cancer cell membranes may provide homologous targeting, erythrocyte membranes improve circulation stability and reduce phagocytic clearance, immune cell membranes enhance immunomodulatory activity, and synthetic lipids can improve fluidity, fusion behavior, and cost efficiency.

Preclinical examples illustrate the breadth of this approach. A red blood cell membrane-coated, polydopamine-wrapped ZIF-8 nanoformulation loaded with hydroxycamptothecin showed prolonged circulation and enhanced immune evasion in vivo. Brain microvascular endothelial cell membrane-coated doxorubicin nanoparticles crossed the blood-brain barrier via macropinocytosis, enabling targeted delivery for brain tumor therapy in preclinical models. Electrochemically active membranes derived from the bacterium Shewanella oneidensis MR-1, produced by LIME, have been combined with titanium dioxide or gold nanoparticles to amplify superoxide generation under low-dose X-ray irradiation or disrupt cellular redox processes. Hybrid membranes fusing 4T1 cancer cell membranes with bacterial outer membrane vesicles yielded an ultrasound-responsive platform combining tumor targeting, immunomodulation, and stimulus-responsive therapy. In infection models, platelet membrane-coated bimetallic MOFs generated reactive oxygen species for broad-spectrum antibacterial activity, while macrophage membrane-coated dendritic nanoplatforms carrying polymyxin B and the anti-inflammatory agent sivelestat targeted both pathogens and host inflammation in infected lungs.

The applications extend to neurodegeneration, ophthalmology, and gene therapy. Neuron-like cell membrane-coated curcumin nanoparticles homed in on damaged dopaminergic neurons in Parkinson’s disease mouse models, suppressing neuroinflammation and improving mitochondrial function, while hybrid liposomes fusing platelet membranes with CCR2-overexpressing cell membranes showed dual targeting of amyloid-beta plaques and inflammatory regions in Alzheimer’s disease models. Hybrid retinal endothelial cell and red blood cell membranes neutralized excess vascular endothelial growth factor in choroidal neovascularization, and dendritic cell membrane-coated nanoparticles demonstrated superior mRNA vaccination performance over conventional lipid vectors in preclinical work. The authors conclude candidly that most of these studies remain at the preclinical stage, with biosafety, stability, standardization, yield, and heterogeneity still unresolved, and that future progress will depend on integrating engineering, chemistry, medicine, materials science, and nanobiotechnology into clinically translatable biomimetic platforms.

Subject of Research: Engineering of hybrid and synthetic extracellular vesicles for drug delivery and biomedical applications

Article Title: Engineering hybrid and synthetic extracellular vesicles for emerging biomedical applications

Article References: Huang, Z.-Y., Hsu, F.-Y., Chen, J.-S., & Li, W.-P. (2026). Engineering hybrid and synthetic extracellular vesicles for emerging biomedical applications. AAPS Open, 12(1), Article 60. https://doi.org/10.1186/s41120-026-00199-7

Image Credits: AI Generated

DOI: 10.1186/s41120-026-00199-7

Keywords: extracellular vesicles, exosomes, liposomes, membrane engineering, nanomedicine, drug delivery, bioorthogonal chemistry, metabolic engineering, biomimetic nanoparticles, cancer theranostics, membrane-coated nanomaterials, hybrid membranes